Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.72+0.13 (+1.51%)
At close: 04:00PM EDT
8.72 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Sign in to post a message.
  • F
    FREDERICK
    Fragile X and Rett Syndrome disorders fall under the ASD or Autism Syndrome Disorder, affecting about five million adults in the U.S. and many tens of millions throughout the world. An NDA for Rett Syndrome involving about 15,000 patients, almost all girls in the U.S., is likely; approval is probable within a year. Further studies for Fragile X and ASD will follow. Success is likely. Rett Syndrome (MECP2-related genetically) is rare in males.
    The ASD U.S. market of roughly five million adults is vast, with possible sales in the one to two billion annual range assuming one-thousand dollar per year treatment cost and 20% penetrance. You can challenge these figures. Still, the potential is high for a multi-billion dollar cap company emerging at roughly ten times sales within a few years for ASD, following further studies. Whether or not there is FDA approval for Blarcamesine in treating Rett and other ASD disorders is not critical because other countries would approve usage for some ASD disorders.
    In a large Israeli study, 1/130 women were FMR1 carriers. In the U.S., studies have shown that Fragile X premutation occurs in about 1/151 females and 1/470 males.
    The possible income figures do not include the potential of Anavex 2-273 for PDD and AD, where the total addressable markets (TAMs) are many times higher.
    What also excites me is a potential treatment modality of Anavex 371 for schizophrenia, where the markets are great. Roughly three million people in the U.S. have schizophrenia. About half are untreated. Many homeless have a variety of schizophrenia called hebephrenia. Wouldn’t it be wonderful if there were an effective medical treatment that could help the homeless?
    Having a genetic marker Sigmar 1 for Rx is exciting and will be helpful in treatments.
    I see AVXL’s stock price reaching at least $20 per share within two years, assuming the FDA approves Blarcamesine for Rett Syndrome patients within two years and within a short time later for variations of ASD and possibly PPD and AD.
    Funding will not be a problem. Significant sources of non-dilutive funding are around the corner.
    Blarcamesine and its analogs represent a significant breakthrough in treating neurological disorders. Investors don’t realize yet how powerful this breakthrough will probably be for humanity. I have increased my holdings of AVXL stock to 100,000 shares and am still purchasing.
    I have also purchased 5650 shares of SWAV to hedge my bets. I have made no comments on the SWAV MB.
    My discussions are not just blue-sky promotions.
    My only connection to the company is through stock holdings. I own no leaps or options. I never purchase on margin.
    I am a wealthy retired cancer surgeon who had the good fortune to work in an insane asylum for a while. If my projections fail, I will always have enough money to put food on the table.
    I welcome challenges to my comments. Please don’t expect any responses. I intend to protect my privacy.
  • K
    KO
    Looking for double digits..not that it matters long run but sure would be nice. 18th and June 21 should help. Good times ahead.
  • R
    ROBERT
    In case you haven’t noticed, this is a bear market featuring high inflation and rising interest rates. Stocks with no earnings and/or high multiples, almost regardless of potential or profitability, get clobbered. Warren Buffett used to say that, when the tide goes out (figuratively referring to liquidity), you find out who’s not wearing a bathing suit. Well, the tide is just starting to go out and those without bathing suits are now obvious. I own AVXL but know there is still more risk in the stock price. However, I do believe that we will have an answer before year end regarding the success or failure of the drug and that’s a short time to wait for a potential block buster.

    As for those who are critical of AVXL’s management for not moving faster, consider SAVA’s headlong charge into one PR mistake after another and their loss of credibility. Which do you prefer?
  • g
    georgejjl
    Wednesday 18th May at 11am

    May 18 2022: Bitesize: Anavex Clinical Trial explained
    The Anavex 2-73 UK clinical trial for adults with Rett Syndrome started at Manchester University and Kings’ College, London, in February 2021.

    Recruitment for the children’s trial, also taking place In Manchester and London, is now underway, with the trial due to start imminently.

    In this session, Dr Kaufmann from Anavex Life Sciences Corp. will speak about the science behind the trial and its design and Dr Banka from the University of Manchester will speak about the experiences and outcomes from the adult’s trial in Manchester.

    We will also hear from the parent of an adult who participated in the trial, plus Reverse Rett’s Andy Stevenson will speak about the role of Reverse Rett in recruitment and helping to make the experience as easy as possible for families.

    This session will take place via Zoom on Wednesday 18th May at 11am.

    https://www.reverserett.org.uk/informevents/bitesize-anavex-clinical-trial-explained/

    Good luck and GOD bless,
    Bullish
  • E
    ExperiencedBioPharmGuy
    The rise today was really nothing: once the AD results are released this Summer the share price will be $50 minimum. I bet it at least spikes to $80.
  • F
    FREDERICK
    This message is the first time that I've commented on this MB. I am writing to encourage those suffering.
    I have extended my investments in AVXL and am now down a significant amount of money from AVXLand other purchases made in this bear market. So far, I have purchased 72,000 AVXL shares, and I will buy more shares.
    As a retired physician mildly familiar with statistics, I am impressed with the statistical results of the various P2 studies for PDD, RTT, and AD. While a significant proportion of P2 studies fail in further P3 studies, the AVXL studies rely upon Sigmar 1 MRNA markets as screeners. IMO that lessens the chance for failure significantly of pending P2/3 investigations.
    While NDAs will take time, just one positive P3 study for AD or PDD will likely send AVXL up in price by 50% or more. An NDA application would lead to more significant results in pricing and any usage approval much, much higher. The markets are more than humongous. Risk/reward ratios are absurdly low.
    I continue to buy because I will always have enough money to put food on my table, sharing existence with a beloved wife for over 50 years. I feel blessed.
    .We will have positive results within three months. Indeed, we can survive financially from temporary losses that short a time.
    Thank you for the words of many conscientious commentators.
  • K
    KO
    No regrets @$14 but wish I was buying now. Congrats to all who do or can avg down. I'm tapped but what a steal on a life changing stock. A CO offering successful treatments for those who have none..yet. Gain wealth, help the suffering, a win win.
    Triple digits next year..imo
  • J
    Jerome
    OK, so Tuesday we get a corporate update.

    My expectations is basically ZERO progress. I am very long but I am a realist. The FDA is basically at a complete standstill. They will not get about AVATAR before EXCELLENCE results. They are behind by months on PDUFAs, etc. So we have almost no likelihood of having moved the needle since AVATAR results were announced. Even then they said they "had to take contact" with the FDA. Missling and co move slowly on everything. The proof will truly be in H2 with EXCELLENCE (maybe sooner but I am sandbagging), and of course Alzheimer's and other trial updates. In the meantime, it has been a utter and sheer destruction of shareholder value. It is the WHOLE sector like AVXL. But I do believe Anavex did nothing to help its case with delays and bungled press release on AVATAR which allowed you know who to attack the firm too easily...now we wait at sub $10 levels...I won't sell a share until Alzheimer's trial results come out but I am disappointed overall, how could one not be...
    Bullish
  • K
    KO
    Not too bad. Hopefully the start back up. Even topped SAVA today. Double digits in the forecast if no (fud) rains on our parade. Market so low either buying and/or covering would bring relief. Kept telling the wife I'd double her money quickly, but..nope. Enjoy the Green weekend y'all.
    Bullish
  • g
    georgejjl
    Anavex's Blarcamesine is helping people with Alzheimer's disease.

    https://www.youtube.com/watch?v=U2yDXwNnCTI

    Good luck and GOD bless,
    Alzheimer's Recovery in Anavex Trial Patients, January 2020
    www.youtube.com
  • F
    FREDERICK
    Fragile X and Rett Syndrome disorders fall under the ASD or Autism Syndrome Disorder, affecting about five million adults in the U.S. and many tens of millions throughout the world. An NDA for Rett Syndrome involving about 15,000 patients, almost all girls in the U.S., is likely; approval is nearly certain within a year. Further studies for Fragile X and ASD will follow. Success is likely. Rett Syndrome (MECP2-related genetically) is rare in males.
    The ASD U.S. market of roughly five million adults is vast, with possible sales in the one to two billion annual range assuming one-thousand dollar per year treatment cost and 20% penetrance. You can challenge these figures any way you want. Still, the potential is high for a multi-billion dollar cap company emerging at roughly ten times sales within a few years for ASD, following further studies. Whether or not there is FDA approval for Blarcamesine in treating Rett and other ASD disorders is not critical because other countries would approve usage for some ASD disorders.
    In a large Israeli study, 1/130 women were FMR1 carriers. In the U.S., studies have shown that Fragile X premutation occurs in about 1/151 females and 1/470 males.
    The possible income figures do not include the potential of Anavex 2-273 for PDD and AD, where the total addressable markets (TAMs) are many times higher.
    What also excites me is a potential treatment modality of Anavex 371 for schizophrenia, where the markets are great. Roughly three million people in the U.S. have schizophrenia. About half are untreated. Many homeless have a variety of schizophrenia called hebephrenia. Wouldn’t it be wonderful if there were an effective medical treatment that could help the homeless?
    Having a genetic marker Sigmar 1 for Rx is exciting.
    I see AVXL’s stock price reaching at least $20 per share within two years, assuming the FDA approves Blarcamesine for Rett Syndrome patients within two years and within a short time later for variations of ASD and possibly PPD and AD.
    Funding will not be a problem. Significant sources of non-dilutive funding are around the corner.
    Blarcamesine and its analogs represent a significant breakthrough in treating neurological disorders. Investors don’t realize how powerful this breakthrough will probably be for humanity. I have increased my holdings of AVXL stock to 100,000 shares and am still purchasing.
    I have also purchased 5650 shares of SWAV to hedge my bets. I have made no comments on the SWAV MB. I have largely finished making purchases to avoid misallocation of my funds.
    My discussions are not just blue-sky promotions. I want to share the good news with you.
    My only connection to the company is through stock holdings. I own no leaps or options. I never purchase on margin.
    I am a wealthy retired cancer surgeon who had the good fortune to work in an insane asylum for a while. If my projections fail, I will always have enough money to put food on the table.
    I welcome challenges to my comments. Please don’t expect any responses. I intend to protect my privacy.
  • d
    dc
    no cash needs for 4 years....
  • F
    Frank B
    It’s time to release a true update not regurgitating the same old studies
  • D
    Daniel
    Yesterday was pivotal.
    I know NOTHING of the science but have been in the market for 60 years.
    This is BIG,
  • g
    georgejjl
    $153 million cash on hand and NO long term debt.

    At least 4 years worth of cash on hand.'

    Multiple Phase 3 pivotal trials completed, near competed and in planning.

    Good luck and GOD bless,
    Bullish
  • g
    georgejjl
    Expect NEWS within just 48 hours regarding Anavex Life Sciences.

    Good luck and GOD bless,
  • g
    gert
    Anavex Life Sciences press release (NASDAQ:AVXL): Q1 GAAP EPS of -$0.14 beats by $0.03.Cash and cash equivalents of $153.3 million on March 31, 2022, compared to $152.1 million at fiscal year end September 30, 2021
  • g
    georgejjl
    Do you know what orders of magnitude means

    10X is one order of magnitude increase

    100X is two orders of magnitude increase

    1,000X is 3 orders of magnitude increase

    10,000X is 4 orders of magnitude increase

    orders of magnitude is plural meaning more than 1

    Anavex 3-71 (formerly known as AF710B) is orders of magnitude more potent than donepezil (Aricept)and other agonists acting either on the M1 or the s-1 receptors, respectively,” Fisher said.

    Quote:
    First, s-1 receptors. They are strangers to published AD drug development, though pharmaceutical industry research on compounds active in the CNS comes across them frequently. First identified in the 1970s, these receptors were studied pharmacologically until Austrian researchers cloned the gene (Hanner et al., 1996). In the years after, scientists learned that many endogenous peptides, for example, pregnanolone and neuropeptide Y, interact with these receptors, and subsequent knockout and other biological studies showed they act as chaperones associated with the endoplasmic reticulum (Hayashi and Su, 2007). Unusually for chaperones, a slew of endogenous ligands that act as agonists or antagonists operate the s-1 receptor, Tangui Maurice at INSERM in Montpellier, France, told the audience in Zuers.

    The s-1 receptor’s role in neurodegenerative diseases is poorly understood. One mutation appears to cause juvenile ALS (Al-Saif et al., 2011), but beyond that, data on its genetic contribution remain sparse (see AlzGene listing).

    The receptor is ubiquitous. Besides neurons, astrocytes, oligodendrocytes, and Schwann cells, the liver, spleen, heart, kidney, intestine, and other organs express it. It is a transmembrane protein that lives in the ER, particularly at touch points with mitochondria. There, it modulates calcium and influences the composition of lipid rafts. The receptor becomes active in response to ligand binding and in conditions of ER stress. It protects mitochondria by influencing production of radical oxygen species and expression of the anti-apoptotic gene BCL2. It also sits in the plasma membrane, where it interacts with receptors ranging from TrkB, the muscarinic acetylcholine receptor, to sodium and potassium channels. “The s-1 receptor is an important activity-dependent signaling modulator of multiple intracellular pathways in the cell,” Maurice told the audience in Zuers.

    How can the s-1 receptor influence myriad functions in cells? It does so by way of cooperating with other receptors. At least in some cases, it forms heteromers with them, said Abraham Fisher, Israel Institute for Biological Research, Ness-Ziona (e.g., see Navarro et al., 2010). This constellation is how the s-1 receptor may work as a target for certain drugs. For example, haloperidol treats schizophrenia by acting on the dopamine D2 and s-1 receptors; fluoxetine treats depression through a combined effect on the serotonin and s-1 receptors, and donepezil treats AD through an effect on a cholinesterase and the s-1 receptor.

    In Zuers, both Fisher and Maurice presented their respective efforts at finding small molecules that tickle this receptor in a way that might treat AD better than current drugs do. Fisher introduced AF710B, a bicyclic heterocyclic spiro-compound that he said selectively activates both the muscarinic M1 receptor and the s-1 receptor. In detailing its effects on a list of phenotypic parameters—it increases sAPPa secretion, decreases tau hyperphosphorylation and GSK-3ß activity, decreases Bax, and increases BCL2 expression in mitochondria—Fisher emphasized that the former two effects come through the M1 receptor and the latter two through the s-1 receptor. Unlike previous compounds Fisher developed, which were mainly M1-selective orthosteric agonists, AF710B is an allosteric M1 receptor agonist. Its heteromer-specific effects differentiate it from other M1 agonists and modulators. Fisher claimed that the new compound is exquisitely potent, acting as a cognitive enhancer in rats at 1 to 30 micrograms (not milligrams) per kilogram body weight. According to Fisher, the compound is orally available with a safety margin of more than 50,000 times the minimally active dose. “Those are orders of magnitude more potent than donepezil and other agonists acting either on the M1 or the s-1 receptors, respectively,” Fisher said.

    Fisher proposed that the compound has a unique mechanism of action, whereby it sensitizes the M1 receptor through heterodimerization with the s-1 receptor in the membrane of the ER, adding, however, that heteromerization of these receptors has not been formally proven. “We are looking to license it for drug development,” Fisher said.

    Good luck and GOD bless,
  • J
    John
    Prof. Alexandre Vamvakidis

    Professor Vamvakidis holds 10 international patents in the areas of nootropes, anti-neurodegenerative (anti-Alzheimer), anti-epileptic, anti-depression prototype molecules. He has been published over 80 times in respected medical/scientific journals. Prof. Vamvakidis’ education includes M.Sc Chemistry from Bordeaux University in 1965, M.Sc. Pharmacology from the University of Paris, Medical School in 1975 and M.Sc Biochemistry from the same university in 1975. Prof. Vamvakidis was awarded his Ph.D in Molecular Pharmacology, from the same institution in 1977. Prof. Vamvakidis’ career includes his role as a Research Associate with Ciba-Geigy, Switzerland, Sanofi, France and CNRS, France from 1994 to 2004. In 1984, Prof. Vamvakidis was appointed by the French Ministry of Education as Professor Adjoint of Molecular Phamacology to various French universities, a role which continues to the present.
  • R
    Red
    Seems to me the stock price will Follow the medical science and the day to day trading will bounce around by big money traders. As an investor in this company I am looking 3 years ahead so if the stock was 26 I’d feel better but wouldn’t sell. If the stock was 5 I’d feel low but also think about acquiring more shares. Just my thought.
Advertisement
Advertisement